fda approval status ghk cu “Is GHK-Cu actually worth it?” is genuinely one of the most common questions in my comments, so let me finally answer it properly., The short version: copper peptides have real research behind them, An FDA advisory committee voted

46 Liver disease In a 72-week phase 2 study of patients (n = 320) with metabolic dysfunction-associated steatohepatitis (MASH), semaglutide (0.1, 0.2 or 0.4 mg daily) reduced steatosis but had no effect on fibrosis

Also influences stability, though less dramatically than temperature or light

In the context of cancer, multiple clinical trials using CQ or HCQ either in combination or as monotherapy are currently in progress showing partly promising results in terms of anticancer effects and toxicity in early phase studies

This was more pronounced in trials for early-stage cancers, with protocol exclusion criteria on the basis of organ-system abnormalities and functional status limitations being associated with lower elderly participation (the authors estimate that relaxing those eligibility restrictions would increase their share to 60 percent) (Lewis et al., 2003)

Research demonstrates effects across wound healing, tendon regeneration, gastroprotection, and angiogenesis models